Welcome to our dedicated page for SAB Biotherapeutics SEC filings (Ticker: SABS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SAB Biotherapeutics, Inc. filings document the regulatory record of a clinical-stage biopharmaceutical company developing SAB-142 for type 1 diabetes and other autoimmune diseases. Form 8-K disclosures cover clinical presentations, Regulation FD materials, and material agreements, including manufacturing services for SAB-142.
The company’s filings also describe its capital structure and financing activity, including common stock, pre-funded warrants, public offering agreements and shelf registration use. Proxy materials cover annual meeting matters, director elections, board composition, stockholder voting items and related governance disclosures.
SAB Biotherapeutics, Inc. stockholders approved two major equity-related proposals at a special meeting. First, they approved the potential issuance of more than 19.99% of the company’s outstanding common stock upon conversion of its Series B Convertible Preferred Stock at less than the Nasdaq “minimum price,” a step that may be deemed a change of control under Nasdaq rules.
Second, stockholders approved an amendment to the 2021 Omnibus Equity Incentive Plan that increases the share pool for awards by 24,180,000 shares to an aggregate of 31,932,466 shares and raises the maximum annual “evergreen” increase from 10,000,000 shares to 73,750,000 shares. The Plan amendment passed with 5,089,862 votes for and 951,598 against, while the Series B conversion proposal passed with 5,502,026 votes for and 515,275 against.
SAB Biotherapeutics describes clinical and corporate disclosures in this amended shelf filing. The filing reports that SAB-142 showed a favorable safety profile in Phase 1 across a dose range of 0.03 mg/kg to 2.5 mg/kg, with 0% reported serum sickness and 0% reported anti-drug antibodies, supporting chronic ambulatory dosing. The company states SAB-142 demonstrated sustained immunomodulation and a multi-target mechanism of action analogous to rabbit ATG on parameters correlative to C-peptide preservation.
The prospectus reiterates extensive risk-factor topics and lists permitted methods for secondary distributions by selling stockholders. It also references recent SEC filings, including the 2024 annual report and quarterly and current reports filed in 2025, without providing financial results in the included excerpt.
Alexandra Kropotova, Chief Medical Officer of SAB Biotherapeutics, Inc. (ticker: SABSW), reported a routine insider transaction dated 09/19/2025. The Form 4 shows 1,977 shares of common stock were disposed through withholding to satisfy tax obligations on vested restricted stock units (RSUs). Following the transaction, she beneficially owns 45,272 shares, which include 29,340 vested shares and 15,932 RSUs that remain subject to vesting.
The filing is a standard Section 16 disclosure reflecting tax-withholding on RSU vesting rather than an open-market sale or purchase. The form was signed by Ms. Kropotova on 09/22/2025 and does not disclose any derivative transactions or other changes in ownership form.